Clinical Trials in San Francisco

Showing 1681-1700 of 12,991 trials

PrEP Affect Regulation Treatment Innovation

NCT04899024

This multi-site randomized controlled trial enrolling sexual minority men who use stimulants and are currently taking pre-exposure prophylaxis (PrEP). This randomized controlled trial will test the efficacy of a PrEP Affect Regulation Treatment Innovation (PARTI) condition comprised of a 5-session positive affect intervention delivered during smartphone-based Contingency Management (CM) for directly observed PrEP doses (PARTI+CM) compared to an attention-control condition delivered during CM. The primary outcome is HIV acquisition risk measured using a combination of tenofovir-diphosphate levels in dried blood spots that are indicative of sub-optimal adherence to PrEP and recent condomless anal sex.

Medication AdherenceHIV PreventionStimulant Use

Florida International University239 participantsStarted Jan 2022

San Francisco, California, United States • Miami, Florida, United States

Active Not RecruitingPhase 2< 1 mile

Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral Sclerosis

NCT07023835

Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral Sclerosis

Amyotrophic Lateral Sclerosis (ALS)

Zydus Therapeutics Inc.240 participantsStarted Sep 2025

La Jolla, California, United States • Orange, California, United States • San Francisco, California, United States +14 more locations

PrEP Affect Regulation Treatment Innovation

Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral Sclerosis

Find Trials by Condition in San Francisco

International CRDS Registry

Building Relationship, Improving Dialogue, and Growing Empathy (BRIDGE): An Intervention to Support Decision Making for Critically Ill Children

HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis

Neonatal Seizure Registry - Developmental Functional EValuation

Avelumab With or Without Cetuximab in Treating Patients With Advanced Skin Squamous Cell Cancer

Assessing PFAS Exposure (APEX) for Better Health

A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight

Evaluation of a Non-Implanted Electrical Stimulation Device for Overactive Bladder (OAB)

A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)

A Study of CTD402 in T-ALL/LBL Patients

Endovascular AAA Intervention Using the GORE® EXCLUDER® Conformable AAA Endoprosthesis or Iliac Branch Endoprosthesis

64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)

A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib

International Registry Study of Neutral Lipid Storage Disease (NLSD) / Triglyceride Deposit Cardiomyovasculopathy (TGCV) and Related Diseases

Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)

Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ LEAP-011)

A Study of LY3540378 in Participants With Worsening Chronic Heart Failure With Preserved Ejection Fraction (HFpEF)

A Study of MGC026 in Participants With Advanced Solid Tumors